Bruno Pitard, Ph.D.

Title of speaker
Directeur de Recherche CNRS （フランス国立科学研究センター、ディレクター）
Co-founder of In-Cell-Art　（インセルアート、共同創設者）

Profile of speaker
Ph.D, Bruno Pitard started his career at Rh?ne Poulenc Rorer (Sanofi-Aventis). Then, he worked at Aventis Pasteur for the DNA vaccine program. After several years spent in academic research (CNRS, INSERM), he established In-Cell-Art with Jean-Marie Lehn, a Nobel Prize laureate. He has contributed to more than 65 publications and 15 patents on nucleic acids and protein formulation.

* 学会プログラムでご案内しておりました講演予定のBruno Pitard氏が急遽来日できなくなりましたため、同社Business Development & Alliance ManagementのSohei Fukuyama氏が代理で講演致します。

ICANtibodies? is a fully integrated process from plasmid DNA antigen design and synthesis, Nanotaxi?/plasmid formulation and immunization in various species to antibody quality controls. In the absence of recombinant protein, In-Cell-Art patented Nanotaxi? allows for the development of functional antibodies against any natively expressed antigen. In-Cell-Art has achieved an important technological breakthrough and is able to produce novel antibodies against membrane targets as well as intracellular, nuclear and secreted antigens.

ICANtibodies? では、DNA免疫用プラスミドのデザイン・合成から、Nanotaxi?/プラスミドベクターの作製、さまざまな種への免疫、抗体の評価まで一貫したサービスを提供しております。

In Cell Art社の特許技術であるNanotaxi?を用いれば、ターゲットタンパク質のAccession No.情報だけで、ターゲットに対する機能的な抗体を得ることができます。In Cell Art社ではこのNanotaxi?技術により細胞内、核、分泌タンパク質はもちろん、作製が困難とされる膜タンパク質ターゲットに対する新規抗体を得ることができます。

The features of ICANtibodies?;

• ? No recombinant proteins and peptides are required to discover antibodies
• ? Only in-silico DNA sequence of target is needed from a customer
• ? Affinity constants for discovered antibodies mostly lie in very wide range (~pM).
• ? Discovered antibodies are specific to targets under their conformational and native structure
• ? A solution to obtain antibodies against difficult targets such as complex of integral membrane proteins and multispanning membrane proteins with high homology (~100%)
• ? Discovered antibodies are for many applications (WB, IHC, ELSA, Pull-down assay and FACS)
• ? Human antibodies are also possible to discover, using transgenic animals reconstituted with the human immune system
• ? More than 250 different antibodies have been discovered for less than 2.5 years